Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023
February 28, 2024 at 04:38 pm EST
Share
Amphastar Pharmaceuticals, Inc. reported impairment of long-lived assets for the fourth quarter ended December 31, 2023. For the quarter, the company reported impairment of long-lived assets of $1,000.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
AMPHASTAR PHARMACEUTICALS, INC. 
